Bio-Techne (TECH) Director Reports 08/15/2025 Share Sales and Long-Term Equity Grants
Rhea-AI Filing Summary
Amy E. Herr, a director of Bio-Techne Corp (TECH), reported multiple transactions dated 08/15/2025 affecting both her direct and indirect holdings. The filing shows disposals of 1,040 shares (reported as a direct disposition) and 101 shares sold at $53.60 (reported as indirect, by significant other). The report also records a non-cash acquisition of 279 shares (transaction code M) at $0 and various option and restricted stock unit holdings and vesting schedules. After the reported transactions, beneficial ownership totals are shown as 2,255 and 2,154 shares in different lines, with numerous outstanding stock options and RSUs exercisable or vesting through 2035.
Positive
- Detailed vesting schedules disclosed for options and RSUs through 2035, improving transparency
- Non-cash issuance recorded (279 shares, code M), indicating grant/award rather than market purchase
- Significant remaining long-term equity alignment via multiple options and RSUs exercisable/vesting over several years
Negative
- Dispositions of common stock including a 1,040-share sale and a 101-share sale at $53.60, which reduce insider holdings
- Some holdings are indirect (by significant other), complicating direct attribution of ownership and potential signaling
Insights
TL;DR: Insider reported routine sales and continued significant equity-linked compensation holdings through 2035.
The Form 4 documents both cash sales and non-cash acquisitions for a board director. The 101-share sale at $53.60 is priced and explicit; the larger 1,040-share disposition lacks an indicated price in the provided lines. Multiple stock options and restricted stock units remain outstanding with staggered vesting dates through 2035, indicating ongoing alignment with long-term equity compensation programs rather than a single opportunistic event. The filings list indirect ownership attributable to a significant other for several holdings, which affects aggregation of family-held economic exposure.
TL;DR: Disclosure is detailed and includes vesting schedules, supporting transparency around director compensation.
The Form 4 provides granular vesting schedules for options and RSUs, including fully vested grants and future vesting through 2035. This level of detail supports transparency on potential future share issuances to insiders. The combination of immediate sales and retained long-term instruments is consistent with scheduled liquidity and compensation realization; the filing does not present explicit material governance concerns based on the transactions disclosed.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 119 | $0.00 | -- |
| Exercise | Restricted Stock Units | 160 | $0.00 | -- |
| Grant/Award | Restricted Stock Units | 932 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 2,735 | $0.00 | -- |
| Exercise | Common Stock | 279 | $0.00 | -- |
| Tax Withholding | Common Stock | 101 | $53.60 | $5K |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- This option vests on the earlier of the one-year anniversary of the grant date (2/3/2025) or the date of Bio-Techne's 2025 annual meeting of shareholders. Fully vested. Options to purchase 520 shares vest on each of 8/6/2022, 8/6/2023 and 8/6/2025; and options to purchase 516 shares vest on 8/6/2024. Options to purchase 528 shares vest on 8/15/2023 and 8/15/2025; and options to purchase 524 shares vest on 8/15/2024 and 8/15/2026. Options to purchase 271 shares vest on each of 8/15/2024, 8/15/2025, 8/15/2026 and 8/15/2027. Options to purchase 367 shares vest on each of 8/15/2025, 8/15/2026, 8/15/2027 and 8/15/2028. Options to purchase 86 shares vest on each of 2/3/2026, 2/3/2027, 2/3/2028 and 2/3/2029. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. 119 restricted stock units vest on 8/15/2025 and 118 restricted stock units vest on 8/15/2026. 160 restricted stock units vest on each of 8/15/2025, 8/15/2026 and 8/15/2027. 38 restricted stock units vest on each of 2/3/2026 and 2/3/2027, and 39 restricted stock units vest on 2/3/2028. 311 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 310 restricted stock units vest on 8/15/2028. Options to purchase 912 shares vest on each of 8/15/2026 and 8/15/2027, and options to purchase 911 shares vest on 8/15/2028.
